Moreover, patients with other molecular subtypes of melanoma have been identified over the years: KIT mutated patients, which could benefit from specific tyrosine kinase inhibitors, ref. [4] and NRAS mutated patients, which, unfortunately, are still lacking specific inhibitors [5]. Here, NRAS is linked to melanoma.